Boston Scientific Target of Unusually Large Options Trading (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) saw some unusual options trading activity on Wednesday. Traders acquired 23,490 put options on the stock. This represents an increase of 52% compared to the average volume of 15,480 put options.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

A number of hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC raised its holdings in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares in the last quarter. Valeo Financial Advisors LLC raised its holdings in shares of Boston Scientific by 1.9% in the 2nd quarter. Valeo Financial Advisors LLC now owns 22,038 shares of the medical equipment provider’s stock valued at $2,367,000 after purchasing an additional 417 shares in the last quarter. Valley National Advisers Inc. lifted its position in shares of Boston Scientific by 26.1% during the 2nd quarter. Valley National Advisers Inc. now owns 1,257 shares of the medical equipment provider’s stock worth $134,000 after purchasing an additional 260 shares during the last quarter. Belpointe Asset Management LLC lifted its position in shares of Boston Scientific by 119.4% during the 2nd quarter. Belpointe Asset Management LLC now owns 5,048 shares of the medical equipment provider’s stock worth $542,000 after purchasing an additional 2,747 shares during the last quarter. Finally, RMG Wealth Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth $52,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat Wall Street: Boston Scientific reported $0.80 EPS and $5.29B in sales (sales +15.9%), showing solid underlying growth that supports the company’s long-term story. PR: Q4 results
• Positive Sentiment: Analysts still mostly constructive: Many firms kept buy/overweight ratings and continue to model meaningful upside even after trimming forecasts — that backing can attract buyers after the drop. Benzinga: analysts cutting forecasts
• Neutral Sentiment: Planned board departure announced — a governance change (long‑serving director stepping down) that is notable but not an operational shock. TipRanks: board departure
• Neutral Sentiment: Unusual options activity and heavy put buying increased volatility — option flows amplified the move and can accelerate selloffs or rebounds depending on market makers’ hedging. Barchart: options activity
• Negative Sentiment: Soft 2026 guidance and underperformance in electrophysiology: management gave a cautious revenue/quarterly outlook and flagged weaker EP sales, which triggered the earlier large selloff as it reset near-term growth expectations. Reuters: cautious outlook
• Negative Sentiment: Multiple price-target cuts: several banks trimmed targets (some steeply) after the print — that lowers analyst floor and can weigh on recovery momentum. Benzinga: PT cuts
• Negative Sentiment: New investor class-action inquiry: Levi & Korsinsky announced an investigation into BSX related to the Feb. 4 results, which is a legal overhang until resolved. Newsfile: securities probe
• Negative Sentiment: CEO insider sale disclosed (large block sold in early Feb.) — raises near‑term sentiment concerns even if not unusual for executives. SEC filing: insider sale

Boston Scientific Trading Up 2.8%

Shares of BSX stock opened at $77.60 on Friday. Boston Scientific has a fifty-two week low of $74.86 and a fifty-two week high of $109.50. The company has a 50 day moving average price of $93.90 and a 200 day moving average price of $98.98. The stock has a market capitalization of $115.04 billion, a P/E ratio of 40.00, a price-to-earnings-growth ratio of 1.33 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The firm’s revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts predict that Boston Scientific will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

BSX has been the subject of a number of research analyst reports. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Mizuho decreased their target price on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday. JPMorgan Chase & Co. dropped their price target on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday. Truist Financial decreased their price objective on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a report on Thursday. Finally, The Goldman Sachs Group set a $99.00 target price on shares of Boston Scientific in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $109.32.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.